DRUG MARKETING HEARINGS DEFINITELY THIS SUMMER, KENNEDY AIDE SAYS
Sen. Kennedy (D-Mass.) will hold a hearing on drug marketing practices before his Senate Labor & Human Resources Committee this summer, committee Health Policy Advisor Stephen Keith, MD, told the National Association of Pharmaceutical Manufacturers June 6-8 mid-year meeting in Washington. "We are planning hearings this summer to focus on promotional activities," Keith declared. "We have not scheduled the hearings, but it will be sometime this summer," he said. Another committee staff member suggested that the hearings could be held in July. The 1980s has brought a return of the kinds of pharmaceutical promotional efforts -- such as industry's lavishing gifts to prescribers and sending them on "boondoggles" -- that were subject of committee hearings in the late 1970s, Keith said. "It looks like a lot of the bad stuff is back." Keith described the industry practices as "unsavory," but the physician seemed equally concerned that prescribers are swayed by the promotional schemes. "Physicians are making therapeutic decisions based on nonscientific or nonclinical data criteria, based on how many lunches the detail guy" provides, he said. "Unfortunately, because of time demands on physicians they are increasingly making therapeutic decisions based only upon the recommendation of drug detailers as opposed to clinical, scientific data."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth